Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • News
  • Industry
  • Pharma News
  • Delhi HC upholds...

Delhi HC upholds Bristol Myers' patent for anti-cancer drug Dasatinib, imposes Rs 5L penalty on SP Labs

Farhat NasimWritten by Farhat Nasim Published On 2024-11-09T17:40:27+05:30  |  Updated On 10 Nov 2024 9:24 AM IST
bms cancer drug dasatinib
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

New Delhi: In relief to Bristol-Myers Squibb Holdings Ireland (BMS), the Delhi High Court has upheld its patent for the anti-cancer drug dasatinib and imposed a penalty of Rs 5 lakh on SP Labs for patent infringement.

BMS initially filed the case in 2015, asserting that SP Labs infringed on its patent by marketing a generic dasatinib product in India before the patent’s expiry in April 2020. Despite repeated notices, SP Labs failed to appear in court, leading to an ex-parte ruling and financial penalty in favor of BMS.

On August 27, 2024, the Delhi High Court delivered its ruling in the patent infringement case between Bristol-Myers Squibb Holdings Ireland (BMS) and multiple defendants, including SP Labs, over the drug dasatinib, used in cancer treatment.

BMS sought a permanent injunction against the defendants for infringing its Indian Patent No. IN 203937, which covered dasatinib and its pharmaceutically acceptable salts, solvates, isomers, and prodrugs. This patent was valid until April 12, 2020, yet BMS contended that unauthorized actions by SP Labs and other entities in India, such as advertising and attempting to distribute a generic version, constituted infringement before the expiration date.

In the initial proceedings, the High Court had issued an ex-parte injunction on September 4, 2015, restraining the defendants from manufacturing or selling dasatinib-based products. This order was later made permanent until the patent’s expiry in 2020. Despite the injunction, BMS discovered in November 2016 that a product branded "DASA SPL," which contained dasatinib, was being marketed at the distributor level in India. Investigations revealed that this product was manufactured by SP Labs, based in Bangladesh, which was connected to the Indian entity SP Labs Pvt. Ltd. According to BMS, SP Labs was attempting to bypass Indian patent laws by manufacturing in Bangladesh, where dasatinib was not under patent protection, and then importing the product to India.

The court documents highlighted that BMS had obtained evidence connecting SP Labs in Bangladesh to the Indian defendants, despite the defendants’ claims to the contrary. In previous rulings, including a December 2023 court order, the Delhi High Court had noted connections between SP Labs and Indian distributors, further supporting BMS's argument that SP Labs was circumventing the injunction through its operations in Bangladesh.

In the present 2024 hearing, the court confirmed that SP Labs had been properly notified about the case but had not appeared in court or presented a defense. Given the lack of response from SP Labs and the evidence provided by BMS, the court ruled in BMS's favor. It decreed a cost of Rs 5,00,000 against SP Labs, payable to the Delhi High Court Bar Association Employee Welfare Fund, as a penalty for its non-compliance and continued infringement actions.

The court also acknowledged the validity of BMS's patent and noted that other defendants, who appeared in court, had not commercially launched any infringing products during the patent’s term and had respected the patent’s validity.

The court’s final ruling imposed several notable restrictions and penalties on SP Labs. First, due to SP Labs' absence in court despite receiving proper notification, the court issued an ex-parte decree, holding SP Labs liable for patent infringement and ordering financial penalties.

Furthermore, the defendants who did appear in court acknowledged the validity of BMS’s patent and refrained from launching dasatinib-based products in India during the patent’s active period. It observed;

“The defendant nos. 1 to 3, 5 and 6, did not launch any dasatinib containing product till the expiry of the suit patent on 12 th April, 2024. II. There has been no commercial use by defendant nos. 1 to 3, 5 and 6, of any kind, whatsoever, in relation to dasatinib till date. III. The defendant nos. 1 to 3, 5 and 6, acknowledge the validity of the Patent No. IN 203937, during its term, till the expiry of such patent on 12th April, 2020.”

The court, however, confirmed that SP Labs, identified as Defendant No. 7, infringed upon BMS’s patent by marketing dasatinib under the brand name DASA SPL, thereby substantiating BMS’s infringement claim. Additionally, a significant fine of Rs 5,00,000 was levied against SP Labs.

Subsequently, the court noted;

“The defendant no. 7 has not entered appearance in the matter and had in fact launched the impugned product dasatinib, under the brand name DASA SPL. Considering the fact that the defendant no. 7 has not appeared before this Court despite valid service, and not raised any defence and has rather introduced the impugned product dasatinib under the brand name DASA SPL, and considering the fact that the present suit has been pending since the year 2015, cost of ₹ 5,00,000/- is imposed against defendant no. 7 in favour of DHCBA Employee Welfare Fund. ”

To view the original order, click on the link below:

https://indiankanoon.org/doc/111815577/

bmsdelhi high courtpatentdasatinibsp labspatent infringementcancercancer drugbristol myers newsbristol myers squibb
Farhat Nasim
Farhat Nasim

    Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    Aspirin in Primary Prevention- When to Consider?

    Aspirin in Primary Prevention- When to Consider?

    Featured image representing medico legal

    What's the Role of Expert Opinion in Medical Negligence?

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    View All

    Journal Club Today

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    View All

    Health News Today

    Health Bulletin 08/ May/ 2025

    Health Bulletin 08/ May/ 2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok